Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...

Shares of Danish pharmaceutical giant Novo Nordisk surged close to 14% on Friday after the company announced positive results ...

On Friday, however, Novo Nordisk announced top-line results in yet another trial. While the results don't initially sound as ...

Novo Nordisk is currently leading the market for incretin therapies with semaglutide-based products Ozempic for type 2 ...

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

NEW YORK, NY / ACCESS Newswire / January 27, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about ...

Novo Nordisk has reported 22% weight loss in people who received weekly amycretin injections for 36 weeks, triggering an 11% ...

About Robbins LLP : A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LL have been dedicated to helping shareholders recover losses, improve corporate governance ...

The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.

Investors and analysts reacted immediately to Novo's revelation. The price of Novo's common stock declined dramatically. From ...

Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...

Finally, some good news for Novo Nordisk (NYSE: NVO ... by the numbers -- 22.7% average weight loss over 68 weeks for CagriSema, and 20.7% weight loss for a 72-week regimen of semaglutide 7.2 ...